Loxo Oncology, Inc. (NASDAQ:LOXO) Director Lori Anne Kunkel sold 5,000 shares of the stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $84.91, for a total transaction of $424,550.00. Following the sale, the director now directly owns 15,040 shares in the company, valued at approximately $1,277,046.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Lori Anne Kunkel also recently made the following trade(s):

  • On Tuesday, August 22nd, Lori Anne Kunkel sold 10,000 shares of Loxo Oncology stock. The shares were sold at an average price of $75.17, for a total transaction of $751,700.00.

Loxo Oncology, Inc. (NASDAQ LOXO) opened at $87.15 on Wednesday. Loxo Oncology, Inc. has a 1 year low of $19.03 and a 1 year high of $95.92.

Loxo Oncology (NASDAQ:LOXO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.15). During the same period last year, the firm posted ($0.77) EPS. analysts anticipate that Loxo Oncology, Inc. will post -4.96 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Lori Anne Kunkel Sells 5,000 Shares of Loxo Oncology, Inc. (LOXO) Stock” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/11/08/lori-anne-kunkel-sells-5000-shares-of-loxo-oncology-inc-loxo-stock.html.

A number of large investors have recently bought and sold shares of the stock. FMR LLC grew its position in Loxo Oncology by 12.1% in the 2nd quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock valued at $352,420,000 after buying an additional 472,814 shares during the last quarter. BlackRock Inc. grew its position in Loxo Oncology by 20.6% in the 2nd quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock valued at $128,534,000 after buying an additional 273,291 shares during the last quarter. Alliancebernstein L.P. grew its position in Loxo Oncology by 50.2% in the 2nd quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock valued at $75,121,000 after buying an additional 312,988 shares during the last quarter. Vanguard Group Inc. grew its position in Loxo Oncology by 24.7% in the 2nd quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock valued at $73,351,000 after buying an additional 181,471 shares during the last quarter. Finally, Lord Abbett & CO. LLC grew its position in Loxo Oncology by 372.0% in the 2nd quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock valued at $59,304,000 after buying an additional 582,862 shares during the last quarter.

LOXO has been the topic of several analyst reports. BidaskClub cut shares of Loxo Oncology from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. BTIG Research reaffirmed a “buy” rating and issued a $75.00 target price on shares of Loxo Oncology in a report on Thursday, August 3rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $71.00 target price on shares of Loxo Oncology in a report on Thursday, August 3rd. Zacks Investment Research upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price target on the stock in a research note on Wednesday, August 9th. Finally, Ifs Securities reiterated an “outperform” rating on shares of Loxo Oncology in a research note on Tuesday, August 8th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $80.02.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.